Hormonal
GLP-1 receptor agonists reduce cardiovascular risk (MACE) and improve renal outcomes in patients with Type 2 Diabetes, independent of weight loss.
For patients with Type 2 Diabetes, especially those with heart disease or kidney risks, GLP-1 medications offer significant protection against heart attacks, strokes, and kidney failure. These benefits are independent of weight loss and are supported by extensive clinical trial data. The choice between daily injections, weekly injections, or oral tablets depends on patient preference and tolerance.
A recent meta-analysis including all seven GLP-1RA CVOTs, that is, 42,920 patients, showed a 12% relative risk reduction in MACE during GLP-1RA treatment compared to placebo. Also, significant reductions in all of the separate components of MACE were observed. Treatment with GLP-1RA leads to a 17% reduction in a broad composite kidney endpoint...
Why this rating
Based on multiple large, multicenter, double-blinded, randomized, placebo-controlled cardiovascular outcomes trials (CVOTs) and meta-analyses.
Source
How glucagon-like peptide 1 receptor agonists work
Christine R. Andreasen et al. · Endocrine Connections · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →